Payment overview · 2025
General Payments
$311.83
9 reported records · 5 companies
Healthcare provider profile · identity verified
Ivan S Ayala, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SAN JUAN, PR · NPI 1952345944
Verified facts
What the public records show
CMS Open Payments records show Ivan S Ayala, M.D. received $311.83 in general payments during 2025 across 9 reported records.
Boston Scientific Corporation accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $138.65 | 44.5% | 2 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $75.00 | 24.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $47.50 | 15.2% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $25.68 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.00 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.83 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PBG PUERTO RICO LLC | $122.50 | 5 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $118.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $20.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 480 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
480 | 113 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
480 | 113 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 2322 | 651 |
| Losartan Potassium | Losartan Potassium | 1991 | 577 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1461 | 406 |
| Metoprolol Succinate | Metoprolol Succinate | 1411 | 382 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1239 | 372 |
| Ezetimibe | Ezetimibe | 1125 | 315 |
| Furosemide | Furosemide | 694 | 194 |
| Synthroid | Levothyroxine Sodium | 623 | 157 |
| Simvastatin | Simvastatin | 573 | 172 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 565 | 179 |
| Metformin Hcl | Metformin Hcl | 522 | 148 |
| Clopidogrel | Clopidogrel Bisulfate | 511 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 120 |
| Eliquis | Apixaban | 480 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 436 | 121 |
| Famotidine | Famotidine | 410 | 103 |
| Xarelto | Rivaroxaban | 390 | 102 |
| Carvedilol | Carvedilol | 368 | 95 |
| Fenofibrate | Fenofibrate | 315 | 88 |
| Nifedipine Er | Nifedipine | 307 | 74 |
| Lisinopril | Lisinopril | 287 | 75 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 285 | 90 |
| Gabapentin | Gabapentin | 283 | 78 |
| Irbesartan | Irbesartan | 276 | 83 |
| Omeprazole | Omeprazole | 269 | 60 |
| Spironolactone | Spironolactone | 233 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 63 |
| Enalapril Maleate | Enalapril Maleate | 204 | 62 |
| Atenolol | Atenolol | 201 | 61 |
| Amiodarone Hcl | Amiodarone Hcl | 194 | 50 |
| Sotalol | Sotalol Hcl | 182 | 52 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 177 | 42 |
| Glipizide Er | Glipizide | 167 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 154 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 42 |
| Digoxin | Digoxin | 146 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 145 | 33 |
| Farxiga | Dapagliflozin Propanediol | 134 | 32 |
| Ramipril | Ramipril | 130 | 31 |
| Clonazepam | Clonazepam | 128 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 122 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 32 |
| Candesartan Cilexetil | Candesartan Cilexetil | 98 | 28 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 97 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 93 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 33 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 88 | 23 |
| Montelukast Sodium | Montelukast Sodium | 88 | 21 |
| Allopurinol | Allopurinol | 75 | 22 |
| Glimepiride | Glimepiride | 71 | 21 |
| Jardiance | Empagliflozin | 67 | 22 |
| Januvia | Sitagliptin Phosphate | 61 | 16 |
| Indapamide | Indapamide | 60 | 12 |
| Alprazolam | Alprazolam | 59 | 19 |
| Meclizine Hcl | Meclizine Hcl | 58 | 15 |
| Temazepam | Temazepam | 52 | 19 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Lansoprazole | Lansoprazole | 44 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 18 |
| Verapamil Er | Verapamil Hcl | 43 | 13 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Cilostazol | Cilostazol | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Valsartan | Valsartan | 33 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Finasteride | Finasteride | 28 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Levoxyl | Levothyroxine Sodium | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cozaar | Losartan Potassium | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.83 · 9 records | Boston Scientific Corporation | ELIQUIS, General - Tachy, General - Therapies, LifeVest, NURTEC ODT, Repatha | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error